Entrada Therapeutics, Inc. Files 2023 Annual Report on Form 10-K

Ticker: TRDA · Form: 10-K · Filed: Mar 13, 2024 · CIK: 1689375

Entrada Therapeutics, Inc. 10-K Filing Summary
FieldDetail
CompanyEntrada Therapeutics, Inc. (TRDA)
Form Type10-K
Filed DateMar 13, 2024
Risk Level
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Entrada Therapeutics, Financial Report, Biopharmaceutical, SEC Filing

TL;DR

<b>Entrada Therapeutics, Inc. has filed its 2023 10-K report detailing its financial performance and corporate information.</b>

AI Summary

Entrada Therapeutics, Inc. (TRDA) filed a Annual Report (10-K) with the SEC on March 13, 2024. Entrada Therapeutics, Inc. filed its 2023 Form 10-K on March 13, 2024, reporting on its fiscal year ending December 31, 2023. The company's principal executive offices are located at One Design Center Place, Suite 17-500, Boston, MA 02210. Entrada Therapeutics, Inc. was formerly known as CycloPorters, Inc., with a name change effective November 4, 2016. The filing includes detailed financial statements and disclosures for the fiscal years 2023, 2022, and 2021. The company operates within the Pharmaceutical Preparations industry (SIC code 2834).

Why It Matters

For investors and stakeholders tracking Entrada Therapeutics, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Entrada Therapeutics' financial health, operational status, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's current standing and future prospects. As a clinical-stage biopharmaceutical company, the detailed disclosures in this report are essential for understanding its progress in drug development, potential risks, and overall business strategy, impacting investor confidence and valuation.

Risk Assessment

Risk Level: — Entrada Therapeutics, Inc. shows moderate risk based on this filing. The company is in the clinical stage of development, which inherently carries high risks related to drug efficacy, safety, and regulatory approval, as detailed in typical 10-K filings for biopharmaceutical companies.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand Entrada Therapeutics' cash burn rate, R&D progress, and potential for future financing or partnerships.

Key Numbers

  • 2834 — SIC Code (Pharmaceutical Preparations)
  • 001-40969 — SEC File Number (SEC filing identifier)
  • 24744574 — Film Number (SEC filing identifier)

Key Players & Entities

  • Entrada Therapeutics, Inc. (company) — Filer name
  • CycloPorters, Inc. (company) — Former company name
  • Boston, MA (location) — Business and mailing address
  • 2023-12-31 (date) — Fiscal year end
  • 2024-03-13 (date) — Filing date

FAQ

When did Entrada Therapeutics, Inc. file this 10-K?

Entrada Therapeutics, Inc. filed this Annual Report (10-K) with the SEC on March 13, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Entrada Therapeutics, Inc. (TRDA).

Where can I read the original 10-K filing from Entrada Therapeutics, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Entrada Therapeutics, Inc..

What are the key takeaways from Entrada Therapeutics, Inc.'s 10-K?

Entrada Therapeutics, Inc. filed this 10-K on March 13, 2024. Key takeaways: Entrada Therapeutics, Inc. filed its 2023 Form 10-K on March 13, 2024, reporting on its fiscal year ending December 31, 2023.. The company's principal executive offices are located at One Design Center Place, Suite 17-500, Boston, MA 02210.. Entrada Therapeutics, Inc. was formerly known as CycloPorters, Inc., with a name change effective November 4, 2016..

Is Entrada Therapeutics, Inc. a risky investment based on this filing?

Based on this 10-K, Entrada Therapeutics, Inc. presents a moderate-risk profile. The company is in the clinical stage of development, which inherently carries high risks related to drug efficacy, safety, and regulatory approval, as detailed in typical 10-K filings for biopharmaceutical companies.

What should investors do after reading Entrada Therapeutics, Inc.'s 10-K?

Investors should review the detailed financial statements and risk factors in the 10-K to understand Entrada Therapeutics' cash burn rate, R&D progress, and potential for future financing or partnerships. The overall sentiment from this filing is neutral.

How does Entrada Therapeutics, Inc. compare to its industry peers?

Entrada Therapeutics operates in the biopharmaceutical sector, focusing on developing novel therapeutics. This industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles.

Are there regulatory concerns for Entrada Therapeutics, Inc.?

As a biopharmaceutical company, Entrada Therapeutics is subject to stringent regulations from bodies like the FDA, governing drug development, clinical trials, and marketing approval. Compliance is critical for market access and product viability.

Industry Context

Entrada Therapeutics operates in the biopharmaceutical sector, focusing on developing novel therapeutics. This industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles.

Regulatory Implications

As a biopharmaceutical company, Entrada Therapeutics is subject to stringent regulations from bodies like the FDA, governing drug development, clinical trials, and marketing approval. Compliance is critical for market access and product viability.

What Investors Should Do

  1. Review the company's cash runway and burn rate to assess its financial sustainability.
  2. Analyze the progress and potential risks associated with its drug development pipeline.
  3. Examine any disclosed partnerships or collaborations that could impact future revenue or development.

Key Dates

  • 2023-12-31: Fiscal Year End — Reporting period for the 10-K
  • 2024-03-13: Filing Date — Date the 10-K was officially submitted to the SEC

Year-Over-Year Comparison

This is the company's 2023 annual report (10-K), providing a comprehensive update compared to previous filings.

Filing Stats: 4,446 words · 18 min read · ~15 pages · Grade level 18.3 · Accepted 2024-03-13 07:24:30

Key Financial Figures

  • $0.0001 — ich registered Common Stock, par value $0.0001 per share TRDA The Nasdaq Global Market

Filing Documents

Management's Discussion and Analysis of Financial Condition and Results of Operations 126

Management's Discussion and Analysis of Financial Condition and Results of Operations 126 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk 138

Quantitative and Qualitative Disclosures About Market Risk 138 Item 8.

Financial Statements and Supplementary Data 139

Financial Statements and Supplementary Data 139 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 169 Item 9A.

Controls and Procedures 169

Controls and Procedures 169 Item 9B. Other Information 169 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 170 PART III Item 10. Directors, Executive Officers and Corporate Governance 171 Item 11.

Executive Compensation 171

Executive Compensation 171 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 171

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 171 Item 13. Certain Relationships and Related Transactions, and Director Independence 171 Item 14. Principal Accounting Fees and Services 171 PART IV Item 15. Exhibits and Financial Statement Schedules 172 Item 16. Form 10-K Summary 173 Signatures 174 From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/entradatx to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors Relations section of our website, available at www.entradatx.com. Investors are encouraged to review the Investors Relations section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this Annual Report on Form 10-K. 3 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K (Annual Report) contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), that are based on our management's belief and assumptions and on information currently available to our management. These statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements contained in this Annual Report include,

Business

Item 1. Business Overview We are a clinical-stage biopharmaceutical company aiming to transform the lives of patients by e stablishing a new class of medicines which engage intracellular targets that have long been considered inaccessible . The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through our proprietary, highly versatile and modular EEV platform (EEV Platform), we are building a robust development portfolio of therapeutic candidates. Our first two drug candidates, ENTR-601-44 and VX-670 (previously referred to as ENTR-701), are in clinical trials, and we expect to initiate additional regulatory filings by the end of 2024. We believe that the potential success of our early programs can translate into the efficient development of additional EEV therapeutic candidates and allow us to build portfolios in neuromuscular disease and beyond. Lead Neuromuscular Programs We are initially focused on the development of EEV therapeutics for rare neuromuscular diseases, starting with Duchenne muscular dystrophy (Duchenne or DMD). DMD is caused by genetic mutations that prevent the creation of functional dystrophin, a protein required to maintain the structural integrity of muscle cells. In our neuromuscular disease programs, we link EEVs to small strands of nucleic acids called oligonucleotides, including phosphorodiamidate morpholino oligomers (PMOs). We are developing EEV-PMOs that promote the skipping of these mutations associated with DMD. We believe that our EEV-PMO exon-skipping therapy will enable the production of functional dystrophin to slow, stop or even reverse disease progression. Our most advanced therapeutic candidate, ENTR-601-44, is being developed for patients with DMD that are exon 44 skipping amenable. On July 24, 2023, Entrada received authorization from the United Kingdom Medici

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.